Stay updated with breaking news from Peter ellmark. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months) and overall survival (median 14.3 months) support continued development of mitazalimab in a randomized confir. ....
Alligator Bioscience To Present Positive Phase 2 Mitazalimab Data in ... pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.
OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months) ....
Share: LUND, Sweden, May 5, 2021 /PRNewswire/ Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that preclinical data on its agonist anti-CD40 antibody mitazalimab has been published in the scientific journal Cancer Immunology, Immunotherapy. The published data show that mitazalimab activates dendritic cells and tumor-reactive T cells resulting in enhanced anti-tumor efficacy in combination with a model cancer vaccine. Title: The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells and enhances anti-tumor efficacy of a model cancer vaccine in vivo Journal: Cancer Immunology, Immunotherapy Authors: Adnan Deronic et al. A publication in a prominent peer-reviewed journal such as Cancer Immunology, Immunotherapy is very encouraging and validates our findings. These data further highlight the strong potential for mitazalimab to be comb ....